SYNERON MEDICAL LTD Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/23/2017)
| Balance Sheet | Total Assets | 277,185,000.00 | ROE | – |
| Balance Sheet | Total Equity | 207,420,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -3,849,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 4,511,000.00 | – | – |
| Cashflow | Operating Cash Flow | 8,360,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.01 | Div. Yield | – |
| Income | Net Income | 179,000.00 | P/E | – |
| Income | Shares Outstanding | 34,945,000.00 | P/B | – |
| Income | Total Revenue | 298,102,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Syneron Medical Ltd., designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company´s products, which it sells primarily to physicians and other practitioners, target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin´s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference and laser-assisted lipolysis. On February 13, 2012, the Company acquired Ultrashape Ltd. On March 14, 2012, Syneron acquired substantially all the assets of TransPharma Medical Ltd.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.syneron.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more